Moderna doses first patient in Phase 1 trial for mRNA-4200 cancer therapy

July 16, 2026 7:01 AM

Moderna, Inc. (NASDAQ: MRNA) has dosed the first U.S. participant in a Phase 1 clinical trial evaluating mRNA-4200, an investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found